trans-Ned-19 is a cell permeable and potent nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist. trans-Ned-19 inhibits NAADP-mediated Ca2+ release (IC50 = 6 nM) and also inhibits [32P]NAADP binding (IC50 = 0.4 nM). trans-Ned-19 can be used as a chemical proble since it fluorescentey labels NAADP receptors in intact cells.
ChEBI: Trans-Ned 19 is a member of the class of beta-carbolines that is 2,3,4,9-tetrahydro-1H-beta-carboline-3-carboxylic acid in which one of the methylene protons at position 1 has been replaced by a 3-{[4-(2-fluorophenyl)piperazin-1-yl]methyl}-4-methoxyphenyl group. It has a role as a nicotinic acid adenine dinucleotide phosphate receptor antagonist. It is a member of beta-carbolines, an alpha-amino acid, a monomethoxybenzene, a member of monofluorobenzenes and a N-arylpiperazine.
NAADP (nicotinic acid adenine dinucleotide phosphate) has recently been recognized as a crucial Ca2+-releasing second messenger in several mammalian tissues including pancreatic, brain and cardiac. Ned-19 is a potent inhibitor of NAADP action. It is a selective blocker of cellular NAADP-induced Ca2+-release and can fluorescently label NAADP receptors. Ned-19 blocks NAADP signaling at nanomolar concentrations. In intact cells, Ned-19 blocked NAADP signaling and fluorescently labeled NAADP receptors.The trans-Ned-19 is more potent than the cis form in regard to both inhibition of Ca2+ release (IC50 of 6 nM versus 800 nM) and [32P]NAADP binding (IC50 of 0.4 nM versus 15 μM).
